Status:
UNKNOWN
Presepsin Biomarker for Ventilator-associated Pneumonia Diagnosis in COVID-19 Patients
Lead Sponsor:
San Luigi Gonzaga Hospital
Conditions:
Ventilator Associated Pneumonia
Covid19
Eligibility:
All Genders
18+ years
Brief Summary
This study is observational and double blind. It evaluates the validity of presepsin (a serum biomarker of bacterial infections) as early biomarker of Ventilator Associated Pneumonia. It will be measu...
Detailed Description
This study will be a single center, double blind observational study. Measurements of presepsin blood level will be performed in all patients with interstitial Sars-Cov-2 pneumonia admitted to ICU, a...
Eligibility Criteria
Inclusion
- ICU patients with Sars Cov 2 interstitial pneumonia requiring invasive mechanical ventilation
Exclusion
- Age less than 18 years
- Pregnancy
- Chronic renal failure stage III or more
- End stage liver disease
- Patients already present in the ICU at the beginning of the study
Key Trial Info
Start Date :
December 21 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 21 2021
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04840940
Start Date
December 21 2020
End Date
December 21 2021
Last Update
April 19 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
SCDU Anestesia e Rianimazione, AOU San Luigi Gonzaga
Orbassano, Turin, Italy, 10043